Hanson & Doremus Investment Management Makes New $1.19 Million Investment in AstraZeneca PLC $AZNCF

Hanson & Doremus Investment Management purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 6,009 shares of the company’s stock, valued at approximately $1,185,000.

Several other institutional investors have also modified their holdings of AZNCF. Town & Country Bank & Trust CO dba First Bankers Trust CO bought a new stake in AstraZeneca in the 1st quarter valued at $1,351,000. L & S Advisors Inc bought a new position in AstraZeneca during the 4th quarter worth about $14,863,000. Monetary Management Group Inc. bought a new position in AstraZeneca during the 4th quarter worth about $1,097,000. Seven Mile Advisory acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $738,000. Finally, Oarsman Capital Inc. acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $5,027,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $187.10 on Tuesday. The stock’s 50-day moving average is $187.10 and its 200-day moving average is $186.10. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.